Analysis · Health
When a Kidney Outcome Includes More Than Kidney Failure
By AWEI · AI-compiled · Published · Analysis prepared · 1 source · doi.org
A diabetes drug can reduce an outcome labelled end stage kidney disease without every prevented event being dialysis or a transplant. A 2023 review by Qingyang Shi and colleagues in The BMJ shows why the definition behind a headline matters.
The researchers combined 816 randomised trials involving 471,038 adults with type 2 diabetes. Their network meta-analysis compared 13 drug classes, combining direct comparisons within trials with indirect comparisons through shared alternatives. Eligible trials lasted at least 24 weeks; the search covered evidence available through October 2022.
For kidney outcomes, 54 trials contributed data. Compared with standard treatments, SGLT-2 inhibitors, GLP-1 receptor agonists and finerenone probably reduced the review’s combined kidney outcome. Randomised evidence supports interpreting these as treatment effects, rather than simply associations between taking a medicine and better health. However, confidence depends on the outcome and comparison.
Here is the crucial detail: the combined outcome included long-term dialysis, transplantation and kidney-related death, but also laboratory changes such as a sustained decline in estimated kidney filtration of at least 40%. Those events are not interchangeable. Because trial reporting varied, the researchers used this broader definition and lowered their certainty rating for kidney benefits to moderate.
Other limits also matter. Finerenone evidence came from people who already had chronic kidney disease, limiting transfer to other populations. The review could not establish the benefits and harms of combining these drug classes. Benefits also sat alongside specific harms, including genital infections with SGLT-2 inhibitors and hospital admissions for high potassium with finerenone.
The practical lesson is to read a kidney-protection claim alongside its event definition, comparator and study population. A reduction in a combined outcome can be meaningful evidence, while still leaving uncertainty about how much it changes the chance of dialysis itself.
Sources used for this article (1)
Direct links to the publisher reports used to prepare this article.
- Source 1
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials ['Qingyang Shi', 'Kailei Nong', 'Per Olav Vandvik', 'Gordon Guyatt', 'Oliver Schnell', 'Lars Rydén', 'Nikolaus Marx', 'Frank C. Brosius', 'Reem A. Mustafa', 'Arnav Agarwal', 'Xinyu Zou', 'Yunhe Mao',
